We tested the hypothesis that fibrin structure/function is unfavorably altered in patients following idiopathic venous thromboembolism (VTE) and their relatives. Ex vivo plasma fibrin clot permeability, turbidimetry and efficiency of fibrinolysis were investigated in 100 patients with first-ever VTE, including 34 with pulmonary embolism (PE), 100 first-degree relatives and 100 asymptomatic controls with no history of thrombotic events. Known thrombophilia, cancer, trauma and surgery were exclusion criteria. VTE patients and their relatives were characterized by lower clot permeability (p<0.001), lower compaction (p<0.001), higher maximum clot absorbancy (p<0.001), and prolonged clot lysis time (p<0.001) than controls, with more pronounced abnormalities, except maximum clot absorbancy, in the patients versus relatives (all p<0.01). Fibrin clots obtained for PE patients were more permeable, less compact and were lysed more efficiently compared to deep-vein thrombosis patients (all p<0.05) with no differences in their relatives. Being VTE relative, fibrinogen, and C-reactive protein were independent predictors of clot permeability and fibrinolysis time in combined analysis of controls and relatives. We conclude that altered fibrin clot features are associated with idiopathic VTE with a different profile of fibrin variables in PE. Similar features can be detected in VTE relatives. Fibrin properties might represent novel risk factors for thrombosis. However, thrombophilia screening fails to identify predisposing factors in 30-50% of idiopathic VTE patients. 2 Moreover, a family history of VTE has been reported to be associated with VTE occurrence irrespective of major congenital and acquired risk factors.
Venous thromboembolism (VTE) involving deep-vein thrombosis (DVT) and pulmonary embolism (PE) affects 1 to 3 per 1000 persons per year. 1 The pathogenesis of VTE is multifactorial. It is well known that common risk factors such as surgery, trauma, prolonged immobilization, malignancy, pregnancy, or oral contraceptives are consistently associated with VTE. 2, 3 The frequency of hereditary thrombophilia in unselected patients with unprovoked VTE is approximately 25%. 3, 4 The most common thrombophilic factors are prothrombotic polymorphisms such as factor V Leiden (FVL) and prothrombin G20210A. 3, 4 However, thrombophilia screening fails to identify predisposing factors in 30-50% of idiopathic VTE patients. 2 Moreover, a family history of VTE has been reported to be associated with VTE occurrence irrespective of major congenital and acquired risk factors. 5 The thrombin-mediated conversion of plasma fibrinogen into fibrin and the formation of clots relatively resistant to lysis are the final step in the blood coagulation. A balance between clot formation and fibrinolysis largely determines clot stability. The structure of a fibrin clot is influenced by environmental and genetic factors, especially concentrations and functions of fibrinogen. 6 It has been shown that formation of clots composed of compact thin fibrin fiber networks, being resistant to fibrinolysis, predisposes to arterial thrombotic events. Reduced clot permeability and impaired fibrinolysis have been reported in patients with acute myocardial infarction (MI) 7 , a history of MI 8, 9 and following cryptogenic stroke. 10 Data on links between clot properties and VTE are sparse. Curnow et al. 11 showed that hypercoagulable patients with arterial thrombosis or VTE, pregnancy complications or autoimmune diseases have increased fibrin generation and reduced fibrinolysis. It has been
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From demonstrated that increased D-dimer levels indicating enhanced fibrin formation and degradation represent an independent risk factor for future VTE. 12 Hypofibrinolysis in a clot lysis assay has been shown in subjects following the first DVT episode. 13 We hypothesized that abnormal fibrin clot features other than hypofibrinolysis can be detected in VTE patients and clot structure/function differ in relatives of VTE patients compared to controls with no history of thrombotic events, like in relatives of MI patients. 14 The aim of this study was to investigate whether fibrin clot properties are altered in VTE patients and their relatives compared to controls.
Materials and Methods
We investigated white subjects aged 18 to 65 years: (1) 100 patients with a history of firstever idiopathic VTE, (2) 100 first-degree relatives with no history of VTE, MI, or stroke, and (3) 100 age-and sex-matched asymptomatic subjects with no personal or family history of VTE, MI or stroke. The diagnosis of VTE was established by a positive finding of color duplex sonography (visualization of an intraluminal thrombus in calf, popliteal, femoral, or iliac veins). The diagnosis of PE was based on the presence of typical symptoms and positive results of high resolution spiral computed tomography. Patients were analyzed in subgroups according to the initial presentation of VTE (DVT alone, PE alone, or DVT combined with PE). Proximal DVT was defined as thrombosis involving the popliteal or more proximal deep vein segments. Distal (calf) DVT was diagnosed if thrombosis involved any vein segment distal to the knee joint. The VTE patients were recruited at least 7 months after a thrombotic event if anticoagulation with vitamin K antagonists was discontinued at least 4 weeks earlier.
To exclude active DVT in relatives and controls at blood sampling, compression test was performed and yielded negative results. or use of thienopyridines were detected in the patients screened. Finally, 100 patients were confirmed eligible and included in the study. Relatives (n=100) were recruited out of 169 screened individuals (using the same screening protocol), mainly brothers and sisters, of the 72 patients, including two first-degree relatives of 28 patients and one relative of 44 patients.
Controls (n=100) were recruited from 189 screened individuals using the same screening protocol, who represented members of the hospital staff, investigators' friends or collaborators and their family members. Relatives and controls were matched for age, sex, smoking, and medications. 
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The Jagiellonian University School of Medicine Ethical Committee approved the study, and participants provided informed consent in accordance with the Declaration of Helsinki.
Laboratory investigations
Fasting blood samples were drawn from an antecubital vein with minimal stasis at 8 to 10 AM. Lipid profiles, blood morphology, glucose, creatinine, and INR were assayed by routine laboratory techniques. Blood samples (vol/vol, 9:1 of 3.2% trisodium citrate) were centrifuged at 2560 g for 20 minutes, supernatant was aliquoted and stored at -80°C.
Fibrinogen was determined using the Clauss method. High sensitivity CRP was measured by nephelometry (Dade Behring, Marburg, Germany). Fasting total plasma Hcy levels were measured using an immunoassay (IMX System, Abbott Diagnostics, Wiesbaden, Germany).
Immunoenzymatic assays were used to determine in citrated plasma prothrombin fragments and plasminogen activator inhibitor-1 (PAI-1; American Diagnostica). All measurements were performed by technicians blinded to the origin of the samples. Intra-assay and interassay coefficients of variation were <7%.
Fibrin permeation analysis
Fibrin clot permeation was determined using a pressure-driven system. 14, 15 Briefly, 20 mmol/L calcium chloride and 1 U/mL human thrombin (Sigma, St. Louis, MO) were added to 120 μl citrated plasma. After 2 hours of incubation in a wet chamber, tubes containing the clots were connected via plastic tubing to a reservoir of a buffer (0.01 M Tris, 0.1 M NaCl, 1 mM EDTA, pH 7.5) and its volume flowing through the gels was measured within 60 minutes. A permeation coefficient (K s ), which indicates the pore size, was calculated from the equation: K s = QxLxη/txAxΔp, where Q is the flow rate in time t; L, the length of a fibrin gel; η, the viscosity of liquid (in poise); A, the cross-sectional area (in cm 2 ), and Δp, a
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Compaction
Citrated plasma was mixed (3:2) with 0.7 IU/mL thrombin, 0.1% Tween 80 and 20 mM calcium chloride in TBS, and then clots were formed in tubes prepared like in the permeation experiments. 15 After centrifugation at 6,000 g for 60 seconds, the volume of the supernatant evacuated from the tubes was assessed on the basis of the difference in weight of the tube.
Compaction was expressed as this volume divided by the initial plasma volume used to form the fibrin clot. The interassay and intraassay coefficients of variation were 7.5 (n=60) and 7.1 % (n=82), respectively.
Turbidity measurements
Plasma citrated samples were mixed 2:1 with a Tris buffer, containing 0.6 U/mL human thrombin (Sigma) and 50 mmol/L calcium chloride to plasma initiated polymerization.
Absorbance was read at 405 nm with a Perkin-Elmer Lambda 4B spectrophotometer (Molecular Devices Corp., Menlo Park, CA). The lag phase of the turbidity curve, which reflects the time required for initial protofibril formation and maximum absorbance at the plateau phase (ΔAbs), indicating the number of protofibrils per fiber, were recorded. 15, 16 The interassay and intraassay coefficients of variation were 7.9 (n=96) and 6.7% (n=150), respectively for the lag phase, and 8.1 (n=96) and 6.9% (n=150), respectively for ΔAbs.
Plasma clot lysis assays
To assess efficiency of clot lysis, two different methods with slight modifications were used.
In the first assay, 17 100 μl citrated plasma was diluted with 100 μl of a Tris buffer, containing respectively for the former, and 9.4 (n=48) and 8.3 % (n=48), respectively, for the latter variable.
Genotyping
The FXIII Val34Leu and alpha fibrinogen Thr312Ala polymorphisms were determined by the polymerase chain reaction followed by the restriction fragments length polymorphism analysis as described previously.
19,20

Statistical analysis
Data are expressed as mean ±SD or as median (interquartile range) unless otherwise stated.
The Kolmogorov-Smirnov test was used to assess conformity with a normal distribution.
Mean values of continuous variables between the 3 groups were compared by two-way ANOVA followed by Tukey's post-hoc test. Categoric values were analyzed using the χ2 test or Fisher's exact test as appropriate. For nonparametric analysis, differences between groups were assessed by the Kruskal-Wallis test. Correlations between the individual parameters were calculated using the Spearman's rank correlation method. To identify independent factors, we used linear regression analysis in which a p-value of 0.05 or less in a simple regression analysis was used as the criterion for entry into the model. A p-value <0.05 was considered statistically significant.
Results
Of the 100 VTE patients 66 subjects had DVT without symptomatic PE (proximal DVT, n=36), and 34 subjects had symptomatic PE (DVT combined with PE, n=22, and PE alone, n=12 (Table 3A) . Moreover, all clots made from plasma of PE patients collapsed at 80 min of percolation during the lysis assay, while in the DVT alone group, the corresponding median time was 100 min (range 80 to 140 min; p=0.01). Similarly, distributions of FXIII Val34Leu and alpha fibrinogen Thr312Ala allelic variants in DVT and PE patients as well as their relatives were similar (data not shown).
The comparison of the PE+DVT (n=22) and PE alone (n=12) subgroups showed no significant differences between the two subgroups with regard to plasma fibrin clot properties (Table 3B) .
Correlations of fibrin clot variables in all the three groups have been shown in Table 4 . As Multiple linear regression model incorporating relatives and control subjects with K s and t 50%
as dependent variables (Table 5) showed that subject status (relative vs control), fibrinogen (per 1 g/L), and CRP (per 1 mg/L) remained independent common predictors of both fibrin variables. Multiple linear regression model incorporating only VTE patients (Table 6) revealed 
. Analysis incorporating all the 300 individuals studied showed that being a VTE patient, fibrinogen, and CRP were identified as independent predictors of both K s and t 50% (Table 7) . Moreover, D-dimer predicted K s while tPA and PAI-1 predicted t 50% .
Discussion
This study is the first to demonstrate that altered clot properties and reduced susceptibility to lysis occur not only in patients with previous VTE, but also in their first-degree relatives compared to well matched controls with no personal or familial history of arterial or venous thrombotic events. In VTE patients with no established acquired or genetically determined thrombotic risk factors, including thrombophilic defects, we found that plasma fibrin clots contain smaller pores, are composed of thicker fibers, however fibrils are formed after similar lag phases, compared to those made from plasma obtained from healthy individuals and patients' relatives. Importantly, we provided evidence that VTE patients and their relatives share some common clot features such as lower permeability, reduced compaction, greater maximum absorbancy and longer lysis time, compared to controls. This suggests genetic background of idiopathic VTE. However, all these features, except maximum absorbancy, were more pronounced in VTE patients, indicating that additional factors or previous thrombosis per se enhance alterations in fibrin clot variables.
Susceptibility of fibrin clots to lysis in VTE patients is probably a crucial fibrin feature from a pathophysiological point of view. It is known that impaired transport of proteins through networks results from compact clot structure and a fibrin clot with loosely packed fibers has a faster fibrinolysis rate. 6 Using a different methodology, ie. clot lysis assay with addition of exogenous thrombin, we confirmed previous findings that impaired plasma fibrin clot lysis characterizes patients following the first episode of DVT. 13 Another approach based on the clot permeation system appears less sensitive to VTE-associated changes in fibrin clot 21 it is likely that a choice of a clot lysis assay to determine efficiency of fibrinolysis is of importance while considering the utility of various lysis assays in clinical settings. In the current study, we failed to show differences between VTE patients and controls in the velocity of D-dimer release from fibrin clots subjected to rtPA in a perfusion assay and used successfully in other patients' groups. 8, 17 Differences in concentrations of reagents and assay design appear to determine sensitivity of the assay to differentiate between thrombotic patients and controls. Further studies on larger populations are needed to establish which methodological approach is optimal to test clot lysis.
Of note, our findings indicate a marked similarity in fibrin clot characteristics observed in the CAD patients and those with previous VTE. Given growing evidence for the links between cardiovascular disease and VTE, 22 our data support this concept by showing that certain clot features may contribute to increased risk of VTE among patients at high cardiovascular risk.
Since very recently the Tromso study has demonstrated that family history of MI is a risk factor not only for MI, but also for VTE, both total and unprovoked, 23 it is tempting to speculate that alterations in fibrin clot structure/function observed in relatives of MI 14 and VTE patients might represent an additional potential explanation for a link between arterial and venous thrombosis.
An intriguing finding is a difference in fibrin properties between PE and DVT patients. Less compact fibrin structure associated with faster clot lysis seems to characterize subjects who
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From have experienced PE, regardless of the presence of concomitant DVT or not. It might be speculated that a constellation of higher K s , and shorter lysis time, found in PE patients, contributes to clot fragmentation followed by pulmonary embolization. This finding might help identify subjects at risk of PE. However, given the limited number of patients with PE in the current study, these novel observations should be interpreted with caution.
Mechanisms behind altered clot structure/function in VTE patients and its relatives remain unclear. The Leeds Family Study showed that genetic factors contribute modestly to variance in fibrin clot measures, including lysis time (range, 10-40%), while the contribution of environmental factors, being poorly characterized, is much larger. 24 Increased levels of fibrinogen, which is a major predictor of fibrin clot properties, results in faster activation rate, a more dense and tight fibrin network, as well as the formation of thicker fibers. 6, 16 VTE patients displayed associations between some clot features and CRP levels, which, if elevated, can reduce clot permeability and lysis as shown in patients at risk of atherosclerotic vascular disease and those with acute MI. 8, 17 Similar correlations were observed in all the 3 groups in the current study. Despite the fact that increased Hcy levels have been reported to decrease clot permeability and susceptibility to lysis in coronary patients and healthy controls, 25 in VTE patients whose tHcy levels did not differ from those measured in relatives and controls, no such effects have been observed indicating that in VTE patients some unknown confounders operate. Although thrombin concentrations alter fibrin structure in in vitro experiments on purified fibrinogen, 26 we did not observe any associations between plasma F1.2 levels and any fibrin variables in any group. Endogenous thrombin potential (ETP), but not plasma F1.2, has been shown to be associated with VTE. 27 It remains to be established whether ETP correlates with fibrin clot properties determined in the current study. It should be highlighted that alterations in fibrin function/structure, found in VTE patients, cannot be attributed to the activation of coagulation observed in the acute phase of thrombosis because
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From thrombin markers were similar in all the 3 groups and there were no associations of the time from the VTE episode and clot features. The effect of two polymorphisms reported to alter fibrin clot structure/function, ie. FXIII Val34Leu 28 and alpha fibrinogen Thr312Ala, 29 has been ruled out in VTE patients, although other studies yielded also results suggesting such associations. 6 However, similarities in fibrin features observed in VTE patients and relatives
suggested an influence of other as yet unidentified genetic factors.
There is evidence that aspirin, statins, and angiotensin-converting enzyme (ACE) inhibitors, used in the prevention and treatment of cardiovascular disease, may increase the size of clot pores and enhance clot lysis. 6, 7, 17, 30 We failed to show differences in fibrin clot properties associated with the administration of any of these drugs in this study. Lack of drug-induced differences might be related to the patients' characteristics and a low percentage of subjects treated. Regarding statins, two other factors could be of importance. In the current study statin-treated patients who received mostly simvastatin or atorvastatin at a dose of 10 or 20 mg/d had relatively low cholesterol levels, which have been shown to be associated with only 4.4% increase in clot permeability and 11% reduction in lysis time following 40 mg/d simvastatin. 31 Our study has several limitations. The number of study participants was limited. However, all the three groups were meticously selected to minimize the impact of known potential confounders. We determined each variable at a single time point. However, there were no differences in clot variables depending on the time from the VTE occurrence. Exclusion of anticoagulated patients (due to warfarin interference with fibrin tests) and those with two or more VTE episodes resulted in omission of subjects who could have more pronounced fibrin alterations. Our experimental approach did not allow to analyze the effect of blood cells and platelets on fibrin clot structure/function, which can alter for example fibrinolysis. 32 Scanning electron microscopy of fibrin clots has not been performed. We believe that functional
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From plasma-based assays provide more valuable insights into a role of fibrin clots in thrombosis and other diseases. Plasma levels of FVIII, FIX, and FXI that have been identified as risk factors for VTE were not determined. However, to our knowledge there have been no reports showing the impact of their increased levels on clot variables except clot lysis time determined using a tissue factor-induced and rtPA-induced plasma-based lysis assay, showing weak associations with most coagulation factors. 13 Moreover, since lipoprotein(a) levels have been reported to adversely affect clot properties, 33 we cannot exclude that this variable, not measured in the present study, may contribute to VTE-related differences in clot properties.
In conclusion, we have shown that patients with VTE and their relatives have characteristic features of fibrin clot structure/function such as rapid formation of dense clots resistant to lysis and fibrin clot properties differ between PE patients and those with DVT alone. Our study provides new insights into the pathophysiology of idiopathic VTE that might have practical implications. Prospective studies are needed to assess the prognostic value of fibrin clot properties in individuals prior to thrombotic events.
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